Patent classifications
C08G69/02
Resveratrol-based flame retardant materials
A process of forming a resveratrol-based flame retardant small molecule with a phosphonate/phosphinate molecule that includes a chloride group and a terminal functional group.
COMPOSITION FOR GEL POLYMER ELECTROLYTES, GEL POLYMER ELECTROLYTE PREPARED THEREFROM, AND LITHIUM SECONDARY BATTERY COMPRISING SAME
The present invention provides a composition for a gel polymer electrolyte, the composition including: an oligomer represented by Formula 1; an additive; a polymerization initiator; a lithium salt; and a non-aqueous solvent, the additive including at least one compound selected from the group consisting of a substituted or unsubstituted phosphate-based compound and a substituted or unsubstituted benzene-based compound, a gel polymer electrolyte prepared using the same, and a lithium secondary battery.
COMPOSITION FOR GEL POLYMER ELECTROLYTES, GEL POLYMER ELECTROLYTE PREPARED THEREFROM, AND LITHIUM SECONDARY BATTERY COMPRISING SAME
The present invention provides a composition for a gel polymer electrolyte, the composition including: an oligomer represented by Formula 1; an additive; a polymerization initiator; a lithium salt; and a non-aqueous solvent, the additive including at least one compound selected from the group consisting of a substituted or unsubstituted phosphate-based compound and a substituted or unsubstituted benzene-based compound, a gel polymer electrolyte prepared using the same, and a lithium secondary battery.
POLYAMIDE COMPOUND
A novel polymer having self-healing properties is provided. The polyamide compound contains a dicarboxylic acid unit represented by the following formula (1) and a diamine unit represented by the following general formula (2). This polyamide compound is excellent in self-healing properties.
##STR00001##
Multilayer tube
Provided is a multilayer tube that has a layer containing an aliphatic polyamide (such as Polyamide 11 or Polyamide 12), a layer containing a Polyamide 6 composition or Polyamide 6/66/12 composition, a layer containing a saponified ethylene-vinyl acetate copolymer, and a layer containing a semi-aromatic polyamide composition that contains a semi-aromatic polyamide having a specific structure, and further has a fluorine-containing polymer in which a functional group having reactivity with an amino group is introduced into the molecular chain thereof.
Multilayer tube
Provided is a multilayer tube that has a layer containing an aliphatic polyamide (such as Polyamide 11 or Polyamide 12), a layer containing a Polyamide 6 composition or Polyamide 6/66/12 composition, a layer containing a saponified ethylene-vinyl acetate copolymer, and a layer containing a semi-aromatic polyamide composition that contains a semi-aromatic polyamide having a specific structure, and further has a fluorine-containing polymer in which a functional group having reactivity with an amino group is introduced into the molecular chain thereof.
RESVERATROL-BASED FLAME RETARDANT MATERIALS
A process of forming a resveratrol-based flame retardant small molecule with a phosphonate/phosphinate molecule that includes a chloride group and a terminal functional group.
RESVERATROL-BASED FLAME RETARDANT MATERIALS
A process of forming a resveratrol-based flame retardant small molecule with a phosphonate/phosphinate molecule that includes a chloride group and a terminal functional group.
TARGETING NR3B1 FOR TREATMENT OF NASH
Provided herein are methods for one or more of: inhibiting the development of non-alcoholic steatohepatitis (NASH), non-alcoholic liver steatosis (NAFLD), fatty liver disease, liver fibrosis, hepatocellular carcinoma; blocking the biosynthesis of fatty acids and triglycerides; inhibiting de novo lipogeneis. The method comprises administering an effective amount of an agent that interferes with the binding of the estrogen receptor related receptor (NR3B) to a NR3B target to a subject in need thereof.
TARGETING NR3B1 FOR TREATMENT OF NASH
Provided herein are methods for one or more of: inhibiting the development of non-alcoholic steatohepatitis (NASH), non-alcoholic liver steatosis (NAFLD), fatty liver disease, liver fibrosis, hepatocellular carcinoma; blocking the biosynthesis of fatty acids and triglycerides; inhibiting de novo lipogeneis. The method comprises administering an effective amount of an agent that interferes with the binding of the estrogen receptor related receptor (NR3B) to a NR3B target to a subject in need thereof.